Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109231 | 0.85 | ADRB1 (0.33) | MAPTALOX15HSD17B10 | |
| SCHEMBL20109140 | 0.80 | CHRNA7 (0.36) | CHRNA7DRD2SIGMAR1OPRM1MAPT | |
| SCHEMBL20109240 | 0.80 | CHRNA7 (0.36) | CHRNA7DRD2SIGMAR1PHGDHMGLL | |
| SCHEMBL20109216 | 0.80 | MAPT (0.37) | CHRNA7DRD2SIGMAR1PHGDHMGLL | |
| SCHEMBL20113904 | 0.79 | MAPT (0.39) | MAPTATM | |
| SCHEMBL20109230 | 0.79 | GAA (0.34) | DRD2PHGDHMGLLMAPT | |
| SCHEMBL20109232 | 0.77 | HTT (0.33) | MAPTCYP3A4 | |
| SCHEMBL20109217 | 0.77 | GFER (0.41) | DRD2MAPTCYP3A4 | |
| SCHEMBL20109215 | 0.77 | ATM (0.33) | CHRNA7PHGDHMGLLMAPTATM | |
| SCHEMBL20109210 | 0.76 | CHRNA7 (0.33) | CHRNA7DRD2SIGMAR1PHGDHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | CHRNA7 3780/4885DRD2 2561/4885SIGMAR1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.